Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

29 Sept 2020

Abstract excerpt

BACKGROUND: Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age. METHODS: We conducted a phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Immunotherapy and Immune Responses
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32991794
DOI: 10.1056/nejmoa2028436

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsPMID 32991794Read ↗

Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in AdultsSemantic proximity Read ↗

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisSemantic proximity Read ↗

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA VaccineSemantic proximity Read ↗

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine BoosterSemantic proximity Read ↗

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Semantic proximity Read ↗

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read ↗

Competent immune responses to SARS-CoV-2 variants in older adults following mRNA vaccinationSemantic proximity Read ↗

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE TrialSemantic proximity Read ↗

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.Semantic proximity Read ↗

Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domainsSemantic proximity Read ↗

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineSemantic proximity Read ↗

Serum Neutralizing Activity of mRNA-1273 Against the SARS-CoV-2 B.1.1.529 (Omicron) Variant: A Preliminary ReportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.